5) Time for a Biotech Reassessment
Is it time for this sector too cool off a bit after a strong run up? Drug development and sales is key in determining the rise and fall of an individual biotech stock, but JP Morgan is taking "a more cautious view" on performance in the overall sector for 2012. Given that these stocks got a jumpstart at the beginning of the year, JP Morgan says, it is "less willing to broadly chase the sector at current levels.''
The companies getting moved to Neutral from Overweight are Amgen (AMGN), ViroPharma (VPHM) and Acorda (ACOR). Meanwhile, JP Morgan recommends putting profits into Gilead Sciences (GILD) or Celgene (CELG) in the large-cap sector, or InterMune (ITMN), Medivation (MDVN) or Alexion (ALXN)in the mid-cap sector.
Biotech stocks on the Nasdaq are up 8.3% so far this year, while the New York Stock Exchange's biotechnology index BTK is up 13.8%. Among the factors that have boosted the broader market are Bristol-Meyers Squibb's (BMY) acquisition of Inhibitex (INHX) and drug launches by Dendreon (DNDN) and Regeneron Pharmaceuticals (REGN).Amgen shares, up 25% in the last two months, have beaten both the S&P 500 index and the broader biotech gains on the Nasdaq. While JP Morgan raised its December 2012 price target on Amgen to $75 from $70 a share, it says that the stock isn't compelling right now. "A restructuring or an increase in the payout ratio seems unlikely near term with the new management team," writes the analysts. "We don't think there are a lot of efficiency gains to be made going forward, especially with Amgen's consistent focus on innovation." The firm's management team is expected to be in place by mid-year. ViroPharm and Acorda, similarly, have outperformed the broader sector recently, and may have limited upside. ViroPharm shares have already seen a run up after the company announced late 2011 that its exclusivity on Vancocin had been extended for three years. A sustained rally in Acorda stocks is uncertain given that it may already reflect the market's optimism toward the company's key drug labels and trials. "With the initial patient backlog now fully cleared for Ampyra, and a focus today more on a DTC type of commercial effect, we see more slow and steady market share gains ahead for Ampyra rather than an inflection point," writes JP Morgan. -- Written by Chao Deng in New York. >To contact the writer of this article, click here: Chao Deng. >To follow the writer on Twitter, go to: @chao_deng >To submit a news tip, send an email to: email@example.com.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV